美尚洁生物A+轮融资数千万元，三类医疗器械布局加速落地

Core Insights - Meishangjie Biotechnology has completed a multi-million RMB A+ round financing led by Su Min Investment and Jintou Zhiyuan, focusing on its innovative humanized collagen products and technology platform [2][4] Group 1: Financing and Investment - The recent financing round will primarily fund the research and clinical trials of Class III medical devices, accelerating product application in aesthetic medicine, burn treatment, surgery, and ophthalmology [4] - The investment is driven by the company's strong technical capabilities and market potential, with a focus on its leading recombinant humanized protein technology platform [4][9] Group 2: Product and Technology - The core competitive advantage of Meishangjie lies in its AI-driven innovation platform, enabling the stable production of high-purity, high-activity type III humanized collagen [5] - Type III collagen, which constitutes 80% of infant skin but drops to about 20% in adults, is crucial for skin elasticity and healing, with the company's recombinant collagen showing three times the biological activity of natural collagen [7] Group 3: Market Application - The product line includes Class II and Class III medical devices, with applications across multiple clinical departments such as plastic surgery, dermatology, surgery, burn treatment, and orthopedics [8] - The growing demand in the aesthetic and anti-aging markets, coupled with increased government support for the biotechnology industry, positions Meishangjie for significant growth [9]